Stifel Reiterates Buy Rating on Pliant Therapeutics (PLRX)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Tech selloff weighs down Wall Street as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Goldman Sachs to acquire real estate company LCN for up to $410M
Pliant Therapeutics (PLRX) PT Lowered to $45 at Oppenheimer
August 8, 2024 8:00 AM EDTOppenheimer analyst Jeff Jones lowered the price target on Pliant Therapeutics (NASDAQ: PLRX) to $45.00 (from $48.00) while maintaining a Outperform rating.... More
Pliant Therapeutics, Inc. (PLRX) Misses Q2 EPS by 7c
August 8, 2024 4:08 AM EDTPliant Therapeutics, Inc. (NASDAQ: PLRX) reported Q2 EPS of ($0.92), $0.07 worse than the analyst estimate of ($0.85).
For earnings history and earnings-related data on Pliant Therapeutics, Inc. (PLRX) click here.
... More